194608-88-3

Basic information

• Product Name: 7-propyl-3-(trifluoromethyl)benzo[d]isoxazol-6-ol
• Synonyms: 7-propyl-3-(trifluoromethyl)benzo[d]isoxazol-6-ol;3-Trifluoromethyl-7-propyl-6-hydroxybenzisoxazole;7-Propyl-3-trifluoromethyl-6-hydroxybenz[4,5]isoxazole;7-dipropyl-6-hydroxy-3-trifluoroMethyl-1,2-benzisoxazole;1,2-Benzisoxazol-6-ol,7-propyl-3-(trifluoromethyl)-
• CAS NO: 194608-88-3
• Molecular Formula: C₁₁H₁₀F₃NO₂
• Molecular Weight: 245.1978096
• Mol File: 194608-88-3.mol

Chemical Properties

• Boiling Point: 323.5 °C at 760 mmHg
• Flash Point: 149.4 °C
• Appearance: /
• Density: 1.355
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 7-propyl-3-(trifluoromethyl)benzo[d]isoxazol-6-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 7-propyl-3-(trifluoromethyl)benzo[d]isoxazol-6-ol(194608-88-3)
• EPA Substance Registry System: 7-propyl-3-(trifluoromethyl)benzo[d]isoxazol-6-ol(194608-88-3)

Safety Data

• Hazardous Substances Data: 194608-88-3(Hazardous Substances Data)

Usage

Uses

As of now, there are no specific applications or uses documented for 7-Propyl-3-(trifluoromethyl)benzo[d]isoxazol-6-ol in the provided materials. However, given its unique structure and the presence of the trifluoromethyl group, it may have potential applications in various fields such as pharmaceuticals, agrochemicals, or materials science. Further research and development would be required to explore and validate its potential uses in these industries.

Upstream product

• 315-44-6 2,4-dihydroxy-1’,1’,1’-trifluoroacetophenone 
• 724466-51-7 1-(2,4-dihydroxy-phenyl)-2,2,2-trifluoro-ethanone oxime 
• 724466-52-8 3-trifluoromethyl-benzo[d]isoxazol-6-ol 
• 724471-16-3 2,4-dihydroxy-3-dipropyl-1',1',1'-trifluoroacetophenone oxime 
• 65239-69-2 2,4-dihydroxy-3-propyl-1',1',1'-trifluoroacetophenone 
• 108-46-3 recorcinol 
• 13331-19-6 2-propyl-1,3-benzenediol 

Downstream Products

• 194608-89-4 {3-chloro-4-[3-(7-propyl-3-trifluoromethyl-benzo[d]isoxazol-6-yloxy)-propylsulfanyl]-phenyl}-acetic acid methyl ester 

Relevant articles and documents

THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS

The present invention relates to novel LXR ligands of Formula (I) and pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

Therapeutic compounds for treating dyslipidemic conditions

The present invention relates to novel LXR ligands of Formula I and pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

Discovery of a novel series of peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes and dyslipidemia

A series of 2-aryloxy-2-methyl-propionic acid compounds and related analogues were designed, synthesized, and evaluated for their PPAR agonist activities. 2-[(5,7-Dipropyl-3-trifluoromethyl)-benzisoxazol-6-yloxy]-2- methylpropionic acid (4) was identified

Therapeutic compounds for treating dyslipidemic conditions

The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

Novel indole-based peroxisome proliferator-activated receptor agonists: Design, SAR, structural biology, and biological activities

The synthesis and structure-activity relationship studies of novel indole derivatives as peroxisome proliferator-activated receptor (PPAR) agonists are reported. Indole, a druglike scaffold, was studied as a core skeleton for the acidic head part of PPAR

THERAPEUTIC COMPOUNDS FOR TREATING DYSLIPIDEMIC CONDITIONS

The present invention relates to novel LXR ligands of Formula I and the pharmaceutically acceptable salts, esters and tautomers thereof, which are useful in the treatment of dyslipidemic conditions, particularly depressed levels of HDL cholesterol.

Method for the prevention and/or treatment of atherosclerosis

The instant invention provides a method for raising serum HDL cholesterol levels comprising administering a therapeutically effective amount of an LXR ligand to a patient in need of such treatment. It further provides a method for using an LXR ligand to stimulate expression of the ABC1 gene. LXR ligands can be used for preventing and treating atherosclerosis and related conditions.

O-Arylmandelic acids as highly selective human PPAR α/γ agonists

A new class of O-arylmandelic acid PPAR agonists show excellent anti-hyperglycemic efficacy in a db/db mouse model of DM2. These PPARα-weighted agonists do not show the typical PPARγ associated side effects of BAT proliferation and cardiac hypertrophy in

Benzisoxazole-derived antidiabetic compounds

The instant invention is concerned with acetylphenols which are useful as antiobesity and antidiabetic compounds. Compositions and methods for the use of the compounds in the treatment of diabetes and obesity and for lowering or modulating triglyceride levels and cholesterol levels or raising high density lipoprotein levels or for increasing gut motility or for treating atherosclerosis are also disclosed.